Bod Science Limited

BOD

AU0000181331

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 04:59:52 23/11/2023 GMT			5-day change	1st Jan Change
0.024 ^AUD	-7.69%		-.--%	-.--%

06-18	Bod Science Further Delays Filing of Half-Year Report	MT
05-29	Bod Science Announces Delay of Half-Year Report Lodgment	MT

Bod Science Limited Announces Company Secretary Changes

January 23, 2023 at 10:10 pm

Bod Science Limited announced the appointment of Carlie Hodges as Company Secretary upon the resignation of Stephen Kelly, effective 23 January 2023. Carlie is a practising corporate and commercial lawyer, holds a Graduate Diploma in Applied Corporate Governance and is a Fellow Member of the Governance Institute of Australia.

Latest news about Bod Science Limited

Bod Science Further Delays Filing of Half-Year Report	06-17	MT
Bod Science Announces Delay of Half-Year Report Lodgment	05-29	MT
Bod Science Announces Delay in Appendix 4D Lodgement	03-25	MT
BOD Science Signs Supply Agreement in Medicinal Cannabis with Green Farmers	12-13	MT
Bod Science Limited Enters into Supply Agreement with Green Farmers	12-13	CI
Bod Science Receives AU$1.6 Million R&D Tax Refund; Shares Rise 8%	11-22	MT
Bod Expects to Receive Funds from Antah Soon	11-21	MT
Bod Science Delays Settlement of Tranche 1 of AU$2.1 Million Placement	11-16	MT
Bod Science Raises AU$2.1 Million Via Share Placement; Shares Fall 43%	11-08	MT
Bod Science Limited announced that it expects to receive AUD 2.05 million in funding	11-07	CI
Australian Shares Retreat as Monthly CPI Indicator Rises	27/09/23	MT
Bod Science Validates Greater Bioavailability of Drug Delivery Technology; Shares Rally 12%	27/09/23	MT
Bod Science Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Bod Science Limited Announces Change of Principal Place of Business	14/08/23	CI
Bod Science Completes Acquisition of Drug Delivery Technology; Shares Up 3%	10/08/23	MT
Bod Australia Limited completed the acquisition of Aqua Phase Ltd.	09/08/23	CI
Bod Science Validates Bioavailability of Aqua Phase Technology	25/07/23	MT
Bod Science Signs Letter of Intent to Sell Medical Cannabis Products in Malaysia	21/06/23	MT
US Debt Ceiling Caution Dampens Appetite for Australian Equities	23/05/23	MT
Bod Australia Secures Ethics Approval for Drug Delivery Study; Shares Jump 10%	23/05/23	MT
Bod Science Limited Announces David Baker Assumes an Additional Advisory Role to Support Management to Progress A Number of Commercial Initiatives	23/04/23	CI
BOD Science Completes Recruiting for Phase IIb Clinical Trial of CBD Product	04/04/23	MT
Bod Science Limited Announces Pharmacokinetic Study to Confirm the Bioavailability of Aqua Phase Submitted for Ethics Approval	27/03/23	CI
Bod Science Completes Screening for Phase 2 Insomnia Trial	13/03/23	MT
Bod Science Limited Provides the Update on Their Phase IIB Clinical trial	12/03/23	CI

Chart Bod Science Limited

Duration

Period

More charts

Company Profile

Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for consumer and medical markets. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Companyâs segments include medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company